Goat anti-Llama IgG (H&L), FITC conjugated

Name: Goat anti-Llama IgG (H&L), FITC conjugated
SKU: AS10 1419
Price: 233 EUR
Availability: InStock

AS10 1419 | Clonality: Polyclonal | Host: Goat | Reactivity: Llama IgG (H&L)

Goat anti-Llama IgG (H&L), FITC conjugated in the group Secondary Antibodies / Anti-Llama / Fluorescent / FITC, TRITC at Agrisera AB (Antibodies for research) (AS10 1419)

Product Information

Immunogen Purified llama IgG (H&L) AAQ19986

Host Goat

Clonality Polyclonal

Purity Immunogen affinity purified goat IgG.

Format Liquid

Quantity 1 mg

Storage Store at 2-8°C. The shelf life is 1 year from date of receipt. Prepare working dilution prior to use and then discard.

Recommended dilution The optimal working dilution should be determined by the investigator. Suggested starting dilution(s): 1 : 20-1 : 2000 for most applications.

Reactivity

Application examples

Additional information

Purity of this preparation is > 95% based on SDS-PAGE. Antibody concentration is 1.0 mg/ml (E 1% at 280 nm = 13.0). Antibody is supplied in 10 mM sodium phosphate, 0.15 M sodium chloride, pH 7.2.1 % (w/v) B, Protease/IgG free. Contains 0.05% (w/v) sodium azide as preservative of bacterial growth.

Based on immunoelectrophoresis, this antibody reacts with heavy chains on llama IgG and light chains on all llama immunoglobulins. Based on immunoelectrophoresis, no reactivity is observed to non-immunoglobulin llama serum proteins.

This antibody will react with VHH of llama IgGs.

Background

Background Goat anti-llama IgG (H&L), FITC conjugated, is a secondary antibody conjugated to FITC, which binds to llama IgG (H&L) in immunological assays. Antibody is affinity purified using solid phase Llama IgG (H&L). Fluorescein-5-isothiocyanate (FITC) has Amax = 494 nm; Emax = 518 nm

Product citations

Selected references Meyer et al. (2014). Antibodies against MERS coronavirus in dromedary camels, United Arab Emirates, 2003 and 2013. Emerg Infect Dis. 2014 Apr;20(4):552-9. doi: 10.3201/eid2004.131746.

Related products: Goat anti-Llama IgG (H&L), FITC conjugated

Goat anti-Llama IgG (H&L), Affinity purified, Unconjugated

AS10 1416 | Clonality: Polyclonal | Host: Goat | Reactivity: Llama IgG (H&L)

206 €

Goat anti-Llama IgG (H&L), Biotin conjugated

AS10 1418 | Clonality: Polyclonal | Host: Goat | Reactivity: Llama IgG (H&L)

233 €

Goat anti-Llama IgG (H&L), HRP conjugated

AS10 1420 | Clonality: Polyclonal | Host: Goat | Reactivity: Llama IgG (H&L)

10 % until e...

233 €

Goat anti-Llama IgG (H&L), TRITC conjugated

AS10 1421 | Clonality: Polyclonal | Host: Goat | Reactivity: Llama IgG (H&L)

233 €

immunogen:	Purified llama IgG (H&L) AAQ19986
Host:	Goat
Clonality:	Polyclonal
Purity:	Immunogen affinity purified goat IgG.
Format:	Liquid
Quantity:	1 mg
storage:	Store at 2-8°C. The shelf life is 1 year from date of receipt. Prepare working dilution prior to use and then discard.
recommended dilution:	The optimal working dilution should be determined by the investigator. Suggested starting dilution(s): 1 : 20-1 : 2000 for most applications.
additional information:	Purity of this preparation is > 95% based on SDS-PAGE. Antibody concentration is 1.0 mg/ml (E 1% at 280 nm = 13.0). Antibody is supplied in 10 mM sodium phosphate, 0.15 M sodium chloride, pH 7.2.1 % (w/v) B, Protease/IgG free. Contains 0.05% (w/v) sodium azide as preservative of bacterial growth. Based on immunoelectrophoresis, this antibody reacts with heavy chains on llama IgG and light chains on all llama immunoglobulins. Based on immunoelectrophoresis, no reactivity is observed to non-immunoglobulin llama serum proteins. This antibody will react with VHH of llama IgGs.
background:	Goat anti-llama IgG (H&L), FITC conjugated, is a secondary antibody conjugated to FITC, which binds to llama IgG (H&L) in immunological assays. Antibody is affinity purified using solid phase Llama IgG (H&L). Fluorescein-5-isothiocyanate (FITC) has Amax = 494 nm; Emax = 518 nm
All references:	Meyer et al. (2014). Antibodies against MERS coronavirus in dromedary camels, United Arab Emirates, 2003 and 2013. Emerg Infect Dis. 2014 Apr;20(4):552-9. doi: 10.3201/eid2004.131746.